Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.
- Felty's syndrome only occurs in those patients with sero-positive RA.They are also positive for anti-cyclic citrullinated peptide (anti-CCP) antibodies.
- This condition occurs in <1% of those with RA.
- The incidence is decreasing with the development and use of more effective treatment for RA.
- Felty's syndrome is most common in people who have had RA for more than 10 years and who have more severe disease with extra-articular manifestations.
The precise cause is unknown.
- Felty's syndrome is an autoimmune disease. The loss of immunological tolerance to self-antigens can cause neutropenia through both peripheral immunological destruction and impaired granulopoiesis. This is traditionally described as a cell-mediated destruction. However, humoral immunity might be important as well in causing neutropenia.
- Felty's syndrome is associated with the HLA-DR4 genotype. This genotype is a marker for more aggressive RA with greater extra-articular manifestations.
- NB: there is a considerable clinico-laboratory overlap between T-cell large granular lymphocytic (T-LGL) leukaemia associated with RA and Felty's syndrome.This suggests that they are just different eponyms for the same clinical entity.
- Can be asymptomatic.
- As a result of neutropenia, affected persons are increasingly susceptible to infections (see 'Complications', below).
- The clinical picture of RA in this scenario is usually one of severe joint destruction contrasting with moderate or absent joint inflammation; and severe extra-articular disease - eg, including rheumatoid nodules, lymphadenopathy, hepatopathy, vasculitis, leg ulcers and skin pigmentation.
- Weight loss.
- Eye symptoms (including dry eyes and irritation due to Sjögren's syndrome and red and painful eyes due to episcleritis).
- Recurrent infections due to neutropenia (lung and skin infections are most common).
- Left upper quadrant pain (due to splenomegaly or splenic infarcts).
- Symptoms related to RA, including joint swelling, pain, stiffness and deformity.
- Typical RA joint deformities ± active synovitis causing joint swelling and tenderness.
- Rheumatoid nodules.
- Features of vasculitis - leg ulcers, brown pigmentation on the legs, periungual infarcts, ischaemia of the extremities.
- Peripheral neuropathy.
- Eye involvement, including episcleritis.
Investigations and diagnosis
There is no specific diagnostic criterion for Felty's syndrome. It is a clinical diagnosis in patients with RA with unexplained neutropenia and splenomegaly.
Relevant investigations may include:
- Blood tests:
- FBC - for neutropenia ± anaemia of chronic disease.
- Autoantibodies - rheumatoid factor and anti-CCP antibody.
- Inflammatory markers (ESR and CRP) may be elevated.
- LFTs - may be raised if there is liver involvement (see 'Complications', below).
- Ultrasound or CT scan to evaluate splenomegaly.
- Bone marrow biopsy:
- May be required to differentiate Felty's syndrome from haematological malignancies - eg, non-Hodgkin's lymphoma.
As Felty's syndrome is rare, information about management relies on small studies and case reports. This condition is difficult to treat and associated with a poor prognosis due to the substantial risk of infections.
Treatment to improve neutropenia
- Immune-modulating drugs: some of these may be the same drugs used to treat the underlying RA.
- Methotrexate is usually first choice, as there is most experience with this drug.
- Various disease-modifying antirheumatic drugs (DMARDs) have been used with mixed success and few data are available on the use of biological agents that might even increase the infection risk.
- Other DMARDs, including hydroxychloroquine, ciclosporin A, sulfasalazine, leflunomide, azathioprine and cyclophosphamide, have also been used in the treatment of Felty's syndrome.
- Rituximab has been used with encouraging results.[4, 9, 10]It is usually reserved for use as a second-line treatment in those patients with refractory Felty's syndrome.
- Other biological agents include the anti-tumour necrosis factor alpha agents, etanercept, infliximab and adalimumab.
- Treatment with granulocyte colony-stimulating factor is a safe and effective treatment in the management of neutropenia associated with Felty's syndrome.
- The dose and frequency of the recombinant human granulocyte colony-stimulating factor should be adjusted at the lowest effective dose.
- Splenectomy is generally reserved for those not responding to medical treatment. Splenectomy is also the treatment of choice for complications of portal hypertension in patients with Felty's syndrome.
- Prevention of infection:
- Immunisation against influenza and pneumococcus.
- Patient awareness to seek immediate treatment for symptoms of infection.
- Splenectomy patients require additional measures for prevention of infection (see separate article Splenectomy, Hyposplenism and Asplenia).
Mangement of splenomegaly
Advise patients about activities, depending on their infection risk and spleen size. For example, advise patients to avoid any activity that could result in blunt trauma to the left upper quadrant (re the risk of splenic rupture).
Management of infectious complications
The most common infections in this scenario affect the skin, mouth, and upper and lower respiratory tract. Any infection should be identified and treated promptly (eg, take swabs/cultures, give appropriate antibacterial or antifungal treatment, etc).
- Overall, patients with Felty's syndrome have a poorer prognosis than those with uncomplicated RA. They have increased morbidity and mortality from infections and malignancy.
- Serious infection is the main cause of death.
- As with all patients with RA, patients with Felty's syndrome also have an increased risk of cardiovascular disease.
- The degree of neutropenia in Felty's syndrome varies with time, and spontaneous remission of neutropenia can occur in up to 40% of patients without specific treatment. However, these patients remain at increased risk of infection despite normal neutrophil counts.
Further reading and references
Felty AR; Chronic arthritis in the adult, associated with splenomegaly and leucopenia. A report of 5 cases of an unusual clinical syndrome. Bulletin of the Johns Hopkins Hospital, Baltimore, 1924, 35:16.
Rozin A, Hoffman R, Hayek T, et al; Felty's syndrome without rheumatoid arthritis? Clin Rheumatol. 2013 May32(5):701-4. doi: 10.1007/s10067-012-2157-3. Epub 2013 Jan 5.
Lazarou I, Petitpierre N, Auger I, et al; Felty's syndrome and hypofibrinogenemia: an unusual target for anti-cyclic citrullinated peptide antibodies? Mod Rheumatol. 2013 Oct 21.
Heylen L, Dierickx D, Vandenberghe P, et al; Targeted Therapy with Rituximab in Felty's Syndrome: A Case Report. Open Rheumatol J. 20126:312-4. doi: 10.2174/1874312901206010312. Epub 2012 Nov 16.
Liu X, Loughran TP Jr; The spectrum of large granular lymphocyte leukemia and Felty's syndrome. Curr Opin Hematol. 2011 Jul18(4):254-9. doi: 10.1097/MOH.0b013e32834760fb.
Bockorny B, Dasanu CA; Autoimmune manifestations in large granular lymphocyte leukemia. Clin Lymphoma Myeloma Leuk. 2012 Dec12(6):400-5. doi: 10.1016/j.clml.2012.06.006. Epub 2012 Sep 19.
Xiao RZ, Xiong MJ, Long ZJ, et al; Diagnosis of Felty's syndrome, distinguished from hematological neoplasm: A case report. Oncol Lett. 2014 Mar7(3):713-716. Epub 2013 Dec 27.
Mahevas M, Audia S, De Lastours V, et al; Neutropenia in Felty's syndrome successfully treated with hydroxychloroquine. Haematologica. 2007 Jul92(7):e78-9.
Tomi AL, Liote F, Ea HK; One case of Felty's syndrome efficiently treated with rituximab. Joint Bone Spine. 2012 Dec79(6):624-5. doi: 10.1016/j.jbspin.2012.01.013. Epub 2012 Mar 7.
Sarp U, Ataman S; A beneficial long-term and consistent response to rituximab in the treatment of refractory neutropenia and arthritis in a patient with Felty syndrome. J Clin Rheumatol. 2014 Oct20(7):398. doi: 10.1097/RHU.0000000000000175.
Narvaez J, Domingo-Domenech E, Gomez-Vaquero C, et al; Biological agents in the management of Felty's syndrome: a systematic review. Semin Arthritis Rheum. 2012 Apr41(5):658-68. doi: 10.1016/j.semarthrit.2011.08.008. Epub 2011 Nov 25.
Newman KA, Akhtari M; Management of autoimmune neutropenia in Felty's syndrome and systemic lupus erythematosus. Autoimmun Rev. 2011 May10(7):432-7. doi: 10.1016/j.autrev.2011.01.006. Epub 2011 Jan 18.
Stock H, Kadry Z, Smith JP; Surgical management of portal hypertension in Felty's syndrome: A case report and J Hepatol. 2009 Apr50(4):831-5. Epub 2009 Feb 12.
I have been on Methotrexate prescribed by my RA specialist for 11 months and only today my GP has said that it COULD be down to this drug and has written a letter to the specialist asking his advice....welshann
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. Patient Platform Limited has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.